The Discovery & Development of ATR-258, a GRK2-Biased β2AR Agonist for the Treatment of Metabolic Disorders
1:30 pm - Thursday 4th March 2027
- Advancing ATR-258 from early discovery into Phase 2 clinical development
- From Type 2 Diabetes and obesity to muscle-preserving weight loss and functional health
- Molecular dynamics calculations reveal a hitherto undescribed β2AR conformation
